Focus: Chengdu New Radiomedicine is a specialized radiopharmaceutical company focused on oncology and neurology applications, operating at mid-stage scale with 51-200 employees in China.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Chengdu New Radiomedicine to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Chengdu New Radiomedicine
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Chengdu New Radiomedicine's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Only NDA-approved product in portfolio; provides near-term revenue foundation with 4+ years of exclusivity remaining.
Multiple ANDA filings represent generic commodity revenue with no differentiation; declining therapeutic value.
Generic reversal agent; minimal differentiation in competitive opioid antagonist space.
Generic immunosuppressant; commoditized indication with minimal margin opportunity.
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo